Navigation Links
Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
Date:10/20/2011

umulation of triglycerides (Davalos et al., PNAS. 2011).  These findings indicate that miR-33a and miR-33b are key regulators of cholesterol and fatty acid metabolism, and that an anti-miR-33 approach can directly impact atherosclerosis, as well as address important cardiovascular risk factors such as obesity, insulin resistance, and hypertriglyceridemia.

Regulus is developing microRNA therapeutics targeting miR-33a/b. The company controls fundamental patent rights related to miR-33a/b, including the miR-33a/b sequence and complementary sequences covered in the Tuschl III patent series. Additional Regulus patent rights include compositions of matter for various chemically modified anti-miR-33a/b compounds and methods of use for the treatment of cardiovascular diseases with anti-miR-33a/b.  

Webinar to be held on October 26, 2011

Dr. Moore and Regulus scientists, Drs. Neil Gibson, Ph.D., Chief Scientific Officer, Hubert Chen, M.D., and Christine Esau, Ph.D., Associate Director Metabolic Disease, will present the data published in Nature and discuss the data's implications in a webinar scheduled for 11:00am EDT on October 26, 2011. To participate in the webinar, register at http://www.videonewswire.com/event.asp?id=82015. Please connect to the webinar several minutes prior to the start time to ensure adequate time for any software download that may be necessary. Questions for the panelists may be submitted during the live event through the web portal. The webinar will be available for replay on the Regulus website at http://www.regulusrx.com.

About microRNA-33a/b

microRNA-33a and b (miR-33a/b), which differ by only two nucleotides, are intronic microRNAs located  within the sterol response elemen
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
2. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
3. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
4. Systemic Lupus Erythematosus Therapeutics (SLE) - Pipeline Assessment and Market Forecasts to 2018
5. Influenza Vaccines Therapeutics - Pipeline Assessment and Market Forecasts to 2018
6. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
7. Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
8. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
9. United Therapeutics Subsidiary Enters Into Contract With National Institutes of Health for Award of up to $45 Million to Support Glycobiology Antiviral Program
10. Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
11. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Worms, Germany (PRWEB) May 21, 2015 ... announces that its manufacturing facility in Worms, Germany ... EXCiPACT™, an independent subsidiary of the International Pharmaceutical ... three Grace facilities that produce its SYLOID® FP ... now received GMP certification, following the Curtis Bay, ...
(Date:5/21/2015)... LOS ANGELES , May 21, 2015 /PRNewswire/ ... research and development company specializing in oncology, today ... 2 clinical trial with aldoxorubicin for the treatment ... of brain cancer.  The open-label, multisite trial is ... of aldoxorubicin in patients whose tumors have progressed ...
(Date:5/21/2015)... 20, 2015 Research and Markets ... the "2015 Global Survey on Flow Cytometry ... The primary goal of this research is ... and reagents. Key information the survey seeks to ... flow cytometers, predominantly used applications for flow cytometers, ...
(Date:5/21/2015)... Ontario (PRWEB) May 21, 2015 ... into an exclusive North American distribution agreement with ... testing system. , With more than 160 years ... products and services for laboratory and production facilities, ... operational excellence and differentiated services to enable science. ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
... GeneGo, Inc., the leading,systems biology tools company, ... develops novel high-throughput methods for cancer,research, drug ... investigating,mechanisms of cancer development and progression, identification ... of action of,anti-cancer compounds. VTT will utilize ...
... Manages Entire Project Information, CAMBRIDGE, England ... Corporation plc (LSE: AU. or AU.L), a,global ... today,announced that Extract Technology, a leading supplier ... biotech markets, has,implemented its Meridio records management ...
... PXS; Nasdaq: PXSL) today announced the appointment of ... of directors., Mr Delaat has 35 years ... the managing director of the Australian,subsidiary of Merck ... until his recent,retirement., During his career Mr ...
Cached Biology Technology:VTT Technical Research Centre of Finland Licenses MetaCore from GeneGo for Cancer Research and Diagnostics 2Autonomy Meridio Enables Extract Technology to Enhance Capabilities in Compliance With Manufacturing Regulations 2Autonomy Meridio Enables Extract Technology to Enhance Capabilities in Compliance With Manufacturing Regulations 3Autonomy Meridio Enables Extract Technology to Enhance Capabilities in Compliance With Manufacturing Regulations 4New Pharmaxis Board Appointment 2
(Date:4/20/2015)... The announcement comes as demand for fire ... Ireland,s foremost records management company, has ... an impressive track record of clients within the first 12 ... management sector in Dubai . As a ... employ a further eight staff members at its Irish headquarters. ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... confident, comfortable and flexible with their eating habits may ... than people who are not. Researchers at Penn State ... eating habits could prove to be an important medical ... were at higher risk of developing cardiovascular disease if ...
... of Technology and Emory University have received a,$1.5 million ... Origins Project," a center for integrated research, education and ... led to the origin of life. The center also ... Jackson State University in Mississippi. The NSF is ...
... or animals) that we consume on a daily basis can ... antibiotics. A doctoral thesis carried out by Jorge Juan Soto ... Analytical Chemistry , at the University of Granada (Universidad de ... Ana Mara Garc a Campaa and Laura G miz Gracia, ...
Cached Biology News:Eating competence may lower risk of heart disease 2Georgia Tech/Emory Center to study origin of life 2Alternative methods proposed to detect pesticides and antibiotics in water and natural food 2
...
Troponin I Immunogen: Full length native protein (purified) (Human). Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-SDF-1β/PBSF affinity isolated antibody lyophilized powder Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline recombinant human SDF-1β/PBSF expressed in E....
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
Biology Products: